Submit your RFI/RFP
Back
Regulatory Affairs
Back
Pharmacovigilance
Pharmacovigilance
Integrated Safety Management from Development to Market
Delivering end-to-end pharmacovigilance services to ensure the highest standards of drug safety and regulatory compliance globally.
Back
Local Affiliate Services
Back
Company
Company
Excellence in Pharmacovigilance & Regulatory Affairs
Superior quality pharmacovigilance and regulatory affairs services helping the pharmaceutical industry make safe and effective healthcare products available worldwide.
  • Home
  • Insights
  • Insuvia Ranks in FT1000 Fastest Growing Companies in Europe

Insuvia Ranks in FT1000 Fastest Growing Companies in Europe

04 March, 2025 Company news
Insuvia Ranks in FT1000 Fastest Growing Companies in Europe

Insuvia Recognized in the Financial Times 1000 Fastest Growing Companies in Europe List for the Third Consecutive Year

Insuvia has been recognized for the third consecutive year in the Financial Times 1000 Fastest Growing Companies in Europe list, ranking 353rd. This achievement highlights our consistent growth, strong business model, and unwavering commitment to excellence in pharmacovigilance and regulatory affairs services.

The FT1000 list, compiled annually by the Financial Times in collaboration with Statista, ranks European companies based on exceptional revenue growth over a defined period. Insuvia’s continued presence among Europe’s fastest-growing businesses underscores our ability to deliver high-quality pharmaceutical and biotech industry solutions while maintaining sustainable expansion.

A Testament to Our Team, Clients, and Partners

This recognition would not be possible without our strong and dedicated team of professionals, whose expertise and commitment drive our success. We also extend our sincere gratitude to our partners and clients, whose trust and collaboration fuel our growth.

At Insuvia, we remain focused on innovation, operational excellence, and industry leadership, ensuring we continue to provide top-tier support in regulatory affairs, pharmacovigilance, and drug safety.

We look forward to continuing this journey of success and achieving even greater milestones together.

Read more about the FT 1000 rankings here: ft.com

Contact
Contact us for more information
Contact type